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Astrocytes, members of the glial family, interact through the exchange of soluble factors
or by directly contacting neurons and other brain cells, such as microglia and endothelial
cells. Astrocytic projections interact with vessels and act as additional elements of the
Blood Brain Barrier (BBB). By mechanisms not fully understood, astrocytes can undergo
oncogenic transformation and give rise to gliomas. The tumors take advantage of the BBB
to ensure survival and continuous growth. A glioma can develop into a very aggressive
tumor, the glioblastoma (GBM), characterized by a highly heterogeneous cell population
(including tumor stem cells), extensive proliferation and migration. Nevertheless, gliomas
can also give rise to slow growing tumors and in both cases, the afflux of blood, via BBB
is crucial. Glioma cells migrate to different regions of the brain guided by the extension of
blood vessels, colonizing the healthy adjacent tissue. In the clinical context, GBM can
lead to tumor-derived seizures, which represent a challenge to patients and clinicians,
since drugs used for its treatment must be able to cross the BBB. Uncontrolled and fast
growth also leads to the disruption of the chimeric and fragile vessels in the tumor mass
resulting in peritumoral edema. Although hormonal therapy is currently used to control
the edema, it is not always efficient. In this review we comment the points cited above,
considering the importance of the BBB and the concerns that arise when this barrier is
affected.
Keywords: glioblastoma, blood-brain barrier, miRNA, exosomes, neural stem cells, tumor-related epileptic seizures,
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THE BLOOD-BRAIN BARRIER
It has been one hundred years since Edwin E. Goldmann dis-
covered the blood-brain barrier (BBB). Using trypan-blue dye
intravenous injections in several animals, he observed that it
spread throughout the body, except for the brain and spinal cord,
which remained unstained. When trypan blue was injected into
the subarachnoid space at the lumbar level, or in the cisterna
magna in young rabbits, the Central Nervous System (CNS),
including the choroid plexus (CP), were stained (Goldmann,
1909; Bentivoglio and Kristensson, 2014), confirming the pres-
ence of a previously unknown barrier between the blood and CNS
structures.
CHOROID PLEXUS
The CP is a structure present in the CNS that also functions
as a tissue barrier. It is responsible for the synthesis of the
cerebrospinal fluid (CSF) and its major proteins, metabolites and
a diversity of other molecules. Anatomically, the CP is a group
of thin membranes located inside the lateral, third and fourth
ventricles. It is basically composed of a monolayer of special-
ized epithelial cells derived from the ependyma that cover the
ventricles walls. This monolayer coats a highly perfused stroma
containing permeable fenestrated blood vessels, fibroblasts, den-
dritic cells and macrophages (Redzic et al., 2005). Its degree of
vascularization exceeds in 10 times those of the brain parenchyma
(Keep and Jones, 1990).
One of the best-described CP-secreted molecules is insulin-
growth factor 2 (IGF2), which promotes neuronal proliferation
and survival in the developing mouse cortex (Lehtinen et al.,
2011). The presence of tight junctions along the basolateral
membrane limits the exchange between the CSF and the CP
connective tissue, preventing the passage of blood-derived cells
and proteins (Vorbrodt and Dobrogowska, 2003). Tight junc-
tions, combined with the expression of several transmembrane
transporters, make CP cells the effectors of the blood-CP-CSF
barrier (Spector, 2010). The CP is also responsible for the
synthesis and generation of nearly two-thirds of the CSF total
volume via the secretion of water, ions and macromolecules
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FIGURE 1 | Schematic representation of the neurovascular unit at
the capillary level. The BBB is composed of several cell types and
ECM molecules in close association. Highly specialized and polarized
endothelial cells, basal lamina, pericytes, and astrocyte endfeet, which
by wrapping the microvessel walls, establish communication with
neurons in the neurovascular unit. The neurovascular unit is important
to maintain optimal brain function. Pericytes and astrocytes are
important in barrier induction and maintenance. Microglia are
CNS-resident immune cells. (Diagram by de Spohr, TCLS). Adapted
from Abbott (2013).
(Johanson et al., 2008). Aquaporins (AQPs) play a pivotal
role in controlling water circulation, particularly AQP-1, which
is present in the membrane of the CP cells (Benga et al.,
1986).
ASTROCYTES
Astrocytes also express AQPs, especially on their endfeet, which
are closely associated with endothelial cells that are also part of
the BBB. Astrocytes contribute to the selection and exchange of
molecules through the barrier, and although a hundred years have
passed since the BBB was discovered, the mechanisms by which
some drugs or parasites enter the brain still remain unsolved. The
BBB is a specialized non-permeable barrier in cerebral microves-
sels. It consists of endothelial cells united by tight junctions,
astrocytic endfeet surrounding blood vessels, pericytes embedded
in the vessel basement membranes (BMs), microglia and neurons,
all playing essential roles in CNS homeostasis (Abbott et al., 2010;
Aryal et al., 2014), as shown schematically in Figure 1. Together,
the components important for BBB integrity and maintenance,
including the extracellular matrix, are known as the neurovascular
unit, which forms a highly coordinated system that dynamically
regulates the cerebral microvascular permeability (Bicker et al.,
2014).
Astrocytes are involved in several other processes important
for normal brain development, such as neurogenesis, myelination,
synapse formation, neuronal migration, proliferation, differen-
tiation, neuronal signaling, production of neurotrophic factors,
formation of scar tissue after neuronal loss, immune activation,
inflammation, and BBB integrity (Anton et al., 1997; Pfrieger and
Barres, 1997; Gomes et al., 1999; Lim and Alvarez-Buylla, 1999; de
Sampaio e Spohr et al., 2002; Rouach et al., 2002; Kielian, 2008;
Diniz et al., 2012; Herculano-Houzel, 2014). Astrocytic endfeet
protrusions interact with microvascular endothelial cells by cov-
ering the capillaries forming the glia limitans. A single astrocyte
may contact multiple capillaries, and this interaction is required
for endothelial cells to acquire properties of the BBB (Hayashi
et al., 1997; Abbott, 2002; Abbott et al., 2006; Obermeier et al.,
2013). Interestingly, astrocytic coverage of vessel endothelial cells
and pericytes is discontinuous at only a few sites, and in these rare
situations microglial processes can be observed touching the basal
lamina (Lassmann et al., 1991; Mathiisen et al., 2010). Gaps in
the endfeet coverage of pericytes occur more frequently, allowing
neuropil elements to contact the basal lamina (Mathiisen et al.,
2010). These astrocytes also interpose in the contacts between
microvessels and neurons, important for coordinating oxygen and
glucose transport for neural activity through regulation of local
blood flow (Zonta et al., 2003; Iadecola, 2004; Takano et al., 2006;
Iadecola and Nedergaard, 2007).
Astrocytes control BBB tightness by secreting soluble factors
that influence endothelial cells. Additionally, the presence of
numerous astrocyte endfeet close to the BBB facilitates the rapid
regulation of BBB permeability, which is important for the innate
immune system in the brain (Prat et al., 2001; Gimsa et al., 2013).
Astrocytes participate in the formation of the BBB by inducing
tight junction formation in endothelial cells, by modulating the
expression and polarization of transporters, and by promoting
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specialized enzyme systems (DeBault and Cancilla, 1980; Janzer
and Raff, 1987; Abbott, 2002; Lee et al., 2003; Haseloff et al., 2005;
Abbott et al., 2006). Astrocytes also up regulate the expression
of ZO-1 and occludin and modulate the redistribution of CD31,
claudin-5 and ZO-1 from a diffuse pattern to the cell borders in
endothelial cells (Siddharthan et al., 2007; Colgan et al., 2008;
Al Ahmad et al., 2011). The interaction between astrocytes and
endothelial cells is a “two-way street”, since endothelial cells also
stimulate astrocyte growth and differentiation (Mi et al., 2001;
Abbott et al., 2006).
Astrocytes induce and maintain barrier properties in endothe-
lial cells postnatally, while during embryonic development these
properties are first regulated by interactions with neural pro-
genitors, and then by pericytes, since in many species, astrocyte
differentiation occurs close to birth (Daneman et al., 2010).
It is possible that astrocyte precursors may determine the fate
of cerebral vascular endothelial cells in the immature neural
environment by releasing soluble factors, as proposed based
on in vitro co-culture experiments by Hayashi et al. (1997).
Clearly, astrocytes have many features that are important to
BBB physiology. The situation in the brain becomes com-
plex when these astrocytes become malignant, as in astrocy-
toma. Intense neovascularization occurs in the brain around
the tumor region, to contribute to tumor growth. This vas-
cularization originates in endothelial cells, but the vessels
are also constituted by the tumor cells adapted to this new
function.
BBB AND GLIOMA
Gliomas comprise a group of tumors that originate in the
brain. They form a special group of neoplasias for which no
cure is currently available, and only modest progress has been
made in understanding their biology. Their specific denomina-
tion derives from the normal stromal cells of the brain—the
macroglial cells—with which they share morphological traits
and molecular markers, i.e., astrocytes (astrocytomas), oligoden-
drocytes (oligodendrogliomas) and ependymal cells (ependymo-
mas) (Louis et al., 2007). In adults, gliomas account for 29%
of all brain tumors; 80% of malignant primary brain tumors
occurring in patients 65–84 years of age (see Figure 3; Dolecek
et al., 2012). Gliomas also affect children and the most com-
mon pediatric histological types are astrocytomas (52%), primi-
tive neuroectodermal tumors (PNETs), medulloblastomas (21%)
and high-grade gliomas (19%) (Hemmati et al., 2003). Gliomas
are highly heterogeneous, infiltrative and diffuse, with different
degrees of invasiveness (Alves et al., 2011b). They can pene-
trate through the brain, colonizing the entire organ, sending
their invasive cells far beyond the principal tumor mass. Despite
this considerable invasive ability, gliomas rarely leave the ner-
vous tissue to colonize other organs, remaining confined in the
skull, with only little evidence of systemic spread (Louis et al.,
2007).
A universally accepted system for the classification of brain
tumors was developed by the World Health Organization (WHO).
This classification is intended to improve the accuracy of prog-
nosis, and thus the effectiveness of therapeutic management of
patients. Gliomas classification has long been based solely on
the histopathological features of the tumor tissues, obtained
through neurosurgical resections, which are whenever possible,
the first line of therapeutic intervention. The diagnostic crite-
ria include the morphology of the tumor cells, tissue architec-
ture, and the immunohistological marker profiles (Louis et al.,
2007).
The classification also includes a grading system that distin-
guishes four different grades of tumors: grades I, II, III and
IV for astrocytomas and II or III for oligodendrogliomas and
oligoastrocytomas. Lower-grade tumors (grades I and II) tend to
be well differentiated and have few cellular anomalies or atypias,
but in general, they closely resemble their non-neoplastic cellular
counterparts. These tumors contain specific genetic alterations
(Riemenschneider and Reifenberger, 2009) and evidence has been
provided for the existence of progressive accumulation of addi-
tional genetic alterations. This is followed by the evolution of the
tumor to higher grades, i.e., higher malignancy and progression
rates (Louis, 2006).
Higher-grade tumors (grades III and IV) are anaplastic, show-
ing signs of increased vessel density, cellular atypias, high mitotic
activity and elevated cell density. Grade IV astrocytoma, better
known under the name of glioblastoma (GBM) multiformis, or
simply GBM, is the most common and aggressive form of glioma.
Glioblastoma samples are characterized by a very high cell density,
numerous atypias, areas of necrosis, and robust neoangiogenesis.
Two forms of GBM have been identified: de novo GBM, the most
frequent, and secondary GBM, which results from the evolu-
tion of a preceding low-grade astrocytoma (Louis et al., 2007).
Glioblastoma accounts for 54% of all glioma subtypes (Dolecek
et al., 2012). They show a highly aggressive course, poor treatment
response, are incurable and patients have short-term survival
expectancies (Miller and Perry, 2007).
Glioblastoma growth is closely associated with the formation
of new vessels and one of the most serious clinical complication
is the development of vasogenic brain edema, which dramatically
increases the intracranial pressure (ICP) by BBB leakage (Noell
et al., 2012). Glioblastomas are the most vascularized tumors in
humans (Takano et al., 2010) and malignancy grade is directly
related to endothelial proliferation (Daumas-Duport et al., 1988).
Microvessel density is a standard indicator for the prognosis of
patients with GBM. However, vessel formation is highly defective,
resulting in vessels with abnormal morphology and function.
Histologycal samples show vessels with variable diameters and
permeability, heterogeneous distribution and irregular basal lam-
ina (Dvorak, 2003).
One of the most widely accepted arguments to explain inef-
ficient vessel formation in GBM is the relatively high amount of
vascular endothelial growth factor (VEGF) present in the tumor
mass (Bergers and Benjamin, 2003). Vascular endothelial growth
factor is one of the most studied molecules in angiogenesis and
acts mainly as a hypoxia-inducible factor; the areas expressing
highest levels of VEGF are the regions of the necrotic core
(Shweiki et al., 1992). Generally, VEGF is overexpressed in GBM
and is responsible for the crosstalk between the tumor and the
endothelial cells in order to promote angiogenesis.
Besides VEGF over expression, altered AQP expression in
components of the BBB (astrocytic endfeet) has been correlated
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to glioma progression. Aquaporins are a family of integral mem-
brane transport proteins that facilitate water efflux across cell
membranes in response to osmotic gradients. So far, 14 AQPs
have been characterized in humans and rodents (Papadopoulos
and Verkman, 2013). In gliomas, AQP1 is upregulated in vitro
in response to increased glucose consumption and glycolysis
(Hayashi et al., 2007). The expression of AQP8 in human
astrocytomas is associated with the pathological grade, being
directly related to the aggressiveness of the tumor (Zhu et al.,
2013). AQP9, on the other hand, is highly expressed in tumor
stem cells, which are found in the tumor mass and are resis-
tant to most available treatments (McCoy and Sontheimer,
2007).
Aquaporins have been described as key regulators of the BBB
integrity. The AQP4 arrangement through the membrane con-
tributes to edema resolution and it is believed that the upregu-
lation of AQP4 observed in gliomas in vivo is a mechanism of
compensation for the loss of the endfeet and the increase in the
perivascular space (Noell et al., 2012) observed in gliomas.
In the early stages of glioma development there is no appar-
ent disruption of the BBB; tumor own vasculature has not yet
been formed and the tumor mass is sustained by normal brain
vessels. As glioma progresses and aggravates, endothelial cells
derived from normal vessels are roughly separated from the vessel
main structure and form new angiogenic spots associated with
the tumor site. As these cells must migrate when forming new
vessels, they disrupt normal vessel structure to arrive at the
tumor site. Because tumors secrete many different molecules that
alter the normal microenvironment, endothelial cell migration
is impaired, and this impairment is reflected in the vascular
architecture. In GBM, the morphological alterations of blood
vessels involve the formation of fenestrations and tight junctions
disruption. Besides, the thickness of the basal lamina is altered and
perivascular space is increased as well as the number of pericytes
associated to the vessels (Hirano and Matsui, 1975; Bertossi et al.,
1997).
The disruption of the BBB can be detected through magnetic
resonance imaging (MRI), using a contrast medium (CM; Sage
and Wilson, 1994). The standard CM used for GBM diagnosis
in MRI is gadolinium, which under normal conditions is not
able to cross the intact BBB. In the case of GBM, since there is
a disruption of the blood brain barrier, gadolinium can diffuse
into the tissue and characteristic ring enhancing lesions are often
seen.
NEURAL PROGENITOR CELLS CROSS THE BBB AND
DECREASE TUMOR SIZE
It is currently accepted that GBMs can also be derived from tumor
stem cells. As said before, GBMs are heterogeneous, due to the
presence of non-tumor cells such as astrocytes, microglial cells
and endothelial cells (Fonseca et al., 2012; Kahn et al., 2012; Lima
et al., 2012). Endogenous, non-tumoral, neural stem cells are
able to migrate from the subventricular zone (SVZ) toward glial
brain tumors, damaged or regenerating tissue, and inflammation
sites (Aboody et al., 2000; Tang et al., 2003; Synowitz et al.,
2006; Walzlein et al., 2008; Díaz-Coránguez et al., 2013). Through
xenotransplantation of GBM cells and experimentally induced
tumors, it was shown that the number of neuroprogenitor cells
(NPCs) attracted to the tumor bed decreases with age, and that
this correlates with rapid tumor growth (Maslov et al., 2004; Syn-
owitz et al., 2006; Walzlein et al., 2008). Neuroprogenitor cells of
young and old mice have been shown to exhibit antitumorigenic
effects by inducing GBM cell death (Glass et al., 2005; Walzlein
et al., 2008). However, fewer NPCs are observed migrating toward
tumors of older mice (Walzlein et al., 2008), which are larger than
tumors of young mice. Chirasani et al. (2010) showed in vitro,
that NPC-derived bone morphogenetic protein 7 (Bmp 7) acts as
a tumor suppressor, decreasing the proliferation, self-renewal and
tumor-initiation ability of GBM stem cells (Chirasani et al., 2010).
Surprisingly, it has also been shown that neural progeni-
tor cells are able to reach the tumor mass when injected sys-
temically. Neural stem cells were shown to transmigrate across
the BBB and reach intracranial gliomas (Díaz-Coránguez et al.,
2013). Apparently, trans-endothelial migration of NPCs is medi-
ated by CD44 (the same molecule used by activated leuco-
cytes during diapedesis) and can thus be blocked by soluble
hyaluronic acid (its ligand) or anti-CD44 blocking antibod-
ies (Rampon et al., 2008). Hepatocyte growth factor (HGF),
VEGF, PGE2 among other factors present in the conditioned
medium of C6 glioma cells, were also found to induce NPC
transmigration (Díaz-Coránguez et al., 2013). This ability to
cross the barrier created by endothelial cells and astrocytes and
to reach the brain parenchyma is being exploited as a pos-
sible therapeutic approach for many CNS diseases, including
GBM.
EXOSOMES, EXTRACELLULAR miRNAs AND THE
BLOOD-BRAIN BARRIER
Naturally existing extracellular vesicles have been exploited as
carriers for therapeutics to the CNS. Exosomes represent a class of
these vesicles, and emerging evidence describes them as vehicles
that have the ability to cross the BBB. Exosomes are small cup-
shaped extracellular vesicles with diameters ranging from 30 to
100 nm. Exosomes are originated from the endocytic pathway,
generated upon fusion of multivesicular endosomes (MVBs) to
the plasma membrane and the consequent release of intraluminal
vesicles (ILVs) of MVBs into the extracellular environment. At
this point, ILVs are referred to as exosomes (Simons and Raposo,
2009; Raposo and Stoorvogel, 2013). The potential of exosomes
to cross the BBB and dispatch molecules to the brain was
first demonstrated by Alvarez-Erviti et al. (2011), who designed
therapeutic exosomes and delivered them into the mouse brain
(Alvarez-Erviti et al., 2011). Cells from bone marrow of C57BL/6
mice were harvested and stimulated with interleukins to pro-
duce immature dendritic cells, which were engineered to express
Lamp2b, an exosomal membrane resident protein, fused with the
rabies virus glycoprotein (RVG), which is internalized by brain
cells upon specific interaction with the acetylcholine receptor.
Purified exosomes released by dendritic cells were loaded with
exogenous GAPDH siRNA or BACE 1 siRNA by electroporation,
and systemically injected into mice in an allogeneic way. Specific
gene knockdown was observed in neurons, microglia and oligo-
dendrocytes, suggesting efficient exosome uptake by these cells. In
another report, exosomes were used to entrap anti-inflammatory
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drugs, which were then delivered to the mouse brain by intranasal
administration (Zhuang et al., 2011). The anti-inflammatory
agents used were curcumin, a polyphenol compound that exhibits
anti-inflammatory, antineoplastic and antioxidant activity; and
JSI-124, a Stat3—Signal transducer and activator for transcripton
3—inhibitor. The drugs were loaded into exosomes and used
in three different approaches: an LPS-induced brain inflamma-
tion model, experimental autoimmune encephalomyelitis (EAE)
disease and mice bearing intracerebral GL26 tumor cells. The
loaded exosomes rapidly reached the brain and were taken up
by microglial cells. Curcumin exosomes led to induction of
apoptosis of inflammatory microglia cells in the LPS-induced
brain inflammation model. Exosomal curcumin treatment also
delayed and attenuated EAE disease. JSI-124-containing exosomes
significantly reduced brain tumor growth in the GL26 tumor
model. Taken together, these findings suggest the possibility of
using exosomes as drug carriers across biological barriers and as
a promising non-immunogenic means to deliver therapeutics to
the brain.
As cited above, exosomes could be used as vehicle to selectively
deliver therapeutic nucleic acid based or conventional drugs, espe-
cially in those tumors that are difficult to access with chemother-
apeutics due to the BBB (Ohno et al., 2013; Sun and Liu, 2014).
For example, there is a number of in vitro and in vivo microRNAs
(miRNAs) that had been mentioned in the context of altered
signaling pathways, whose expression could represent potential
therapeutic targets in GBM (Sana et al., 2011). The ability of
individual miRNAs to target multiple genes and pathways could
be a major advantage in GBM treatment (Purow, 2011). One of
the most critical issues though, is how to deliver the agent (a
miRNA mimic or inhibitor) to regions protected by the BBB (van
Rooij et al., 2008; Gomes-da-Silva et al., 2013; Mizoguchi et al.,
2013).
Recently, remarkable attention has been paid to the potential of
circulating miRNAs profiling for cancer diagnosis and prognosis
(Kosaka et al., 2010; Fujita et al., 2014). A pilot study demon-
strated that miR-15b and miR-21 assessed in CSF were good
markers for gliomas (Baraniskin et al., 2012). Glioblastoma tumor
cells release exosomes containing miRNAs, messenger RNAs and
angiogenic proteins (Skog et al., 2008; van der Vos et al., 2011;
Yang et al., 2013; Figure 2A). microRNAs are molecules involved
in gene regulation through a mechanism of inhibition or degra-
dation of mRNAs of several known targets (Zhang et al., 2012).
They can be detected in CSF, serum and plasma (Alexandrov
et al., 2012; Teplyuk et al., 2012; Ilhan-Mutlu et al., 2013; Jin
et al., 2013; Figure 2). Extracellular miRNAs are released from
cells enclosed within exosomes, microvesicles, apoptotic bodies
or in protein-miRNA complexes, such as high-density lipoprotein
(HDL) and AGO2, the key effector protein of miRNA-mediated
silencing (Valadi et al., 2007; Zernecke et al., 2009; Arroyo et al.,
2011; Kosaka and Ochiya, 2011; Vickers et al., 2011). microRNAs
detected in CSF of brain-cancer patients may be derived from
brain-cancer cells; from surrounding brain tissues; or from extra-
cranial tissue, as a consequence of BBB disruption and cancer
treatments (Teplyuk et al., 2012). Glioblastoma derived microvesi-
cles are likely to represent one of the mechanisms by which
tumor cells change the brain microenvironment and make it more
permissive for growth and invasion. As such one cannot disregard
them as a powerful, non-invasive approach for diagnosing tumor
progression in cancer patients (Skog et al., 2008).
Despite the large amount of studies mentioning the impor-
tance of circulating miRNAs in the diagnosis and prognosis
of diseases, the exact mechanism that determines or identifies
the circulating miRNAs, and their biological function remains
uncertain. Two theories regarding the export and the function
of circulating miRNA have been suggested. Some researches
defend that circulating miRNA can be key mediators of var-
ious cell-cell communication processes, while others support
the idea that all types of circulating miRNA in the biologi-
cal fluids can be merely by products of cellular activity and
cell death (Turchinovich et al., 2012; Turchinovich and Cho,
2014). Kirschner et al. (2013) highlighted their concern about
the increasing number of reports revealing the clinical potential
of using miRNA levels in body fluids as potential biomark-
ers. According to these authors, the field of cell-free miRNA
research is still in its infancy, and it has failed to adopt a set
of standardized criteria for reporting the methodology used in
the quantification of miRNAs. The delivery of miRNA and the
ability to target specific tissues or cells while avoiding nonspecific
delivery remains challenging. For this reason, RNA carriers, such
as liposomes or exosomes, are under investigation as a possible
source of effective delivery strategies approaches (Santos et al.,
2010; Ohno et al., 2013; Figure 2B). Either way, future research is
needed to improve drug delivery to brain tumors (Ningaraj et al.,
2007).
CLINICAL PROBLEMS RELATED TO GLIOMA TUMORS
CORTICOIDS AND MORBI-MORTALITY IN GLIOMA PATIENTS
One of the main causes of morbidity and mortality in glioma
patients is the induction of severe cerebral edema, which leads to
brain herniation in up to 60% of patients with GBM (Silbergeld
et al., 1991). Cerebral edema, the abnormal accumulation of
water inside the brain parenchyma, is commonly seen in GBM
patients (Figure 3). Peri-tumoral edematous fluid can accumulate
in amounts up to 90 ml per day in severe cases (Ito et al., 1990).
Within the rigid skull, rapid augmentation of brain volume leads
to a sharp increase in ICP, which can result in decreased cerebral
blood flow, ischemia, brain herniation and death (Papadopoulos
et al., 2004).
Brain tumor-related edema (BTRE) is caused by two main
mechanisms, vasogenic and cytotoxic. While BTRE is classi-
cally associated with vasogenic edema, cytotoxic edema is being
increasingly implicated in the pathophysiology of peri-tumoral
swelling (Ito et al., 1990). Vasogenic edema is caused by the dis-
ruption of the BBB, which allows leakage of fluids from the blood
into the brain parenchyma (Ryan et al., 2012). It is hypothesized
that the disturbance of the BBB is due to two main mechanisms:
(1) decreased expression of functioning tight-junctions and dis-
ruption of normally expressed tight-junctions; and (2) increased
endothelial pinocytosis and endothelial fenestrations (Kröll et al.,
2009). Cytotoxic edema, on the other hand, is associated with
glioma-induced neuronal cell death and neurodegeneration, lead-
ing to further brain swelling and neurological deficits (Savaskan
et al., 2008).
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 418 | 5
Dubois et al. Tumors of the CNS and the blood-brain barrier
FIGURE 2 | miRNAs and the Blood-Brain Barrier. MicroRNAs (miRNAs)
are small (≈22 nt) regulatory and non-codified RNAs that are frequently
deregulated in cancer and have shown promise as tissue-based markers
for cancer classification and prognosis. They have emerged as key
regulators of several pathogenic responses, although their role is largely
unknown. The clinical use of siRNA-based therapies is highly promising,
although dependent on the development of nanocarriers with appropriate
features for systemic administration, since these small RNAs have a
unstable structure. Nanocarriers protect the RNA from nuclease
degradation and promote effective regulation of target genes, especially
in brain tumors such as glioblastomas (GBMs) that are somehow
protected from chemotherapeutic drugs by the blood–brain barrier (BBB),
which is meant to protect the brain from noxious agents. Several
strategies have been employed to deliver drugs across this barrier, and
some of these can cause structural damage to the BBB. The ideal method
for transporting drugs across the BBB would be controllable and not
damage the barrier. Among the various presently available approaches,
nanobiotechnology-based delivery methods are the most promising
(A). This image attempts to clarify the action of miRNAs in brain-cancer
cells, through nanocarriers capable of crossing through the BBB.
Exosomes are a class of secreted nanoparticles that have the ability to
carry RNA and proteins, and therefore to be very important mediators of
intercellular communication. The altered characteristics of exosomes in
many diseases, such as cancer, suggests that they could be important for
both diagnostic and therapeutic purposes, for instance as drug-delivery
vehicles, especially for gene therapy as emphasized in this review (B).
Corticosteroids have been used for more than 50 years in the
treatment of BTRE, and have revolutionized the care of brain-
tumor patients (Galicich et al., 1961). Approximately 70% of
glioma patients receive dexamethasone as an adjuvant treatment,
with a significant decrease in deaths (Hempen et al., 2002). In
humans, brain imaging studies with MRI and PET have shown
decreased peritumor water content and reduced tumor capillary
permeability after dexamethasone administration (Jarden et al.,
1989; Sinha et al., 2004). However, although corticosteroids have
been used for a long time, the mechanisms through which they
reduce brain edema are still poorly understood. It has been
suggested that corticosteroids reduce BTRE by decreasing the
permeability of the tumor capillaries (Hedley-Whyte and Hsu,
1986; Heiss et al., 1996). The capillary permeability-reducing
effect is partly explained by upregulation of the tight-junction
protein occluding (Gu et al., 2009). Dexamethasone also mod-
ulates the expression of VEGF in brain-tumor cells as well
as in BBB cells (Kim et al., 2008). In vitro experiments have
shown reduced levels of VEGF and increased concentration of
claudin in response to corticosteroids (Kröll et al., 2009). The
corticosteroid-sparing effects of VEGF-inhibitors such as bevaz-
icumab in GBM patients also provide indirect evidence of a
VEGF-modulation mechanism of dexamethasone (Kreisl et al.,
2009).
Other mechanisms implicated in steroid-reducing BTRE
are reduced angiogenesis and diminished cytotoxicity,
and the anti-inflammatory effect on reducing cytokine-
induced BBB breakdown. Recent evidence has shown that
administration of dexamethasone in a glioma-cell culture
and an animal model reduced glioma-induced neuronal
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FIGURE 3 | Magnetic resonance imaging sequences T1-weighted
with contrast (A) and FLAIR (B) show a left parieto-occipital mass
with high signal on FLAIR and a surrounding area of vasogenic
edema/tumor infiltration. The lesion presents peripheral
heterogeneous contrast enhancement, representing the disruption of
the blood-brain barrier.
damage and normalized vessel morphology and vessel
density in the peritumoral brain area (Fan et al., 2014).
Other studies have shown a 50% reduction in lymphocyte
and microglia peritumoral infiltration when animals are
treated with corticosteroids (Badie et al., 2000). It is
hypothesized that corticosteroid inhibition of NF-κβ causes
reduction of edema via inhibition of cytokine-induced
barrier breakdown and decreasing the expression of cell
adhesion molecules, which mediate T-cell–BBB interactions and
excessive leukocyte recruitment across the BBB (Pitzalis et al.,
2002).
Given the adverse effects of corticosteroids, such as osteoporo-
sis, myopathy and immunosuppression, corticosteroid-sparing
agents are being developed. Corticorelin acetate, a corticotropin-
releasing factor (CRF) analog, was studied in a phase I/II trial
and seems to be well tolerated. Randomized phase III trials
are now envisioned (Villalona-Calero et al., 1998). Not sur-
prisingly, given the prominent role of VEGF in the patho-
physiology of BTRE, VEGF antibodies (e.g., bevazicumab) and
VEGF receptor inhibitors (e.g., cediranib, sorafenib, and suni-
tinib) are being studied (Gerstner et al., 2009). Bevazicumab,
the best-studied agent so far, has already proven to have anti-
edema properties and to have the potential to be a steroid-
sparing agent (Vredenburgh et al., 2010). However, because of
the increased risk of intra-cerebral hemorrhage and pulmonary
thromboembolism, the use of bevazicumab is not yet recom-
mended solely for the purpose of corticosteroid-sparing (Cohen
et al., 2009).
Brain tumor-related edema is a life-threatening complication
of gliomas, and so far, their treatment has relied on the use of cor-
ticosteroids. Steroids have pleiotropic effects on BTRE; however,
due to their numerous side effects, corticosteroid-sparing agents
are being developed as alternatives for BTRE treatment.
TUMOR-ASSOCIATED EPILEPTIC SEIZURES
Epileptic seizures often occur in brain-tumor patients, with
reports of seizure risk of 60–100% among low-grade tumors
and 40–60% in GBM (Vecht et al., 2014). It is the presenting
symptom in 30–50% of the patients, and 10–30% will continue
to have recurrent seizures, which contribute to the morbidity of
the disease. Clinically, tumor-related seizures manifest as simple
or complex partial seizures, with or without secondary generaliza-
tion. A recent study evaluating the seizure semiology and short-
term developments of primary brain tumors, found that the initial
seizures were tonic-clonic in 48% of the patients, focal motor in
26%, complex partial in 10% and somatosensitive in 8%. The
majority of cases (60%) had isolated seizures or a low seizure
frequency at the onset of the disease, whereas a high seizure
frequency or status epilepticus was observed in 18% and 12% of
the cases, respectively (Michelucci et al., 2013).
The incidence of seizures differs widely between low- and
high-grade tumors, probably with different pathophysiological
mechanisms. There is an inverse relationship between the rate of
tumor growth and the risk of seizures, which are more prevalent
in tumors with a slower growth rate (Schaller and Rüegg, 2003;
Chang et al., 2008). Besides the growth rate, the tumor location
is another important element for the development of seizures.
In general, patients with seizures at the onset of disease have a
more-cortical location and are among the patients with a better
prognosis.
Studies suggest that specific symptoms of the disease reflect
not only the location of the tumor but also its biological behavior,
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because patients with low-grade glioma with early seizures in the
beginning of the disease and concomitant early control have a
higher survival rate than those who develop recurrent seizures
(Danfors et al., 2009).
The pathogenesis of tumor-related seizures is complex, mul-
tifactorial and still not fully understood. The mechanisms of
epileptogenesis differ among tumor types. The intrinsic epilepto-
genicity of glioneuronal tumors is supported by electrocorticog-
raphy and surgical and immunocytochemical studies, suggesting
the presence of a hyperexcitable neuronal component (Ferrier
et al., 2006). The role of specific neuronal populations in epileptic
foci was studied by comparing epileptic and nonepileptic cortex
removed from patients with low-grade gliomas. Epileptic and
nearby (within 1 to 2 cm) nonepileptic temporal lobe neocor-
tex was identified using electrocorticography. Cortical specimens
taken from four patients identified as epileptic and nonepilep-
tic were all void of tumor infiltration. Somatostatin- and γ-
aminobutyric acid (GABAergic)-immunoreactive neurons were
identified and counted. Although there was no significant dif-
ference in the overall cell count, the authors found a significant
decrease in both somatostatin- and GABAergic-immunoreactive
neurons (74% and 51%, respectively) in the epileptic cortex com-
pared to that in the nonepileptic cortex from the same patient.
These findings suggest that changes in neuronal subpopulations
may have a role in the onset and propagation of epileptiform
activity in patients with low-grade gliomas. Gliosis and chronic
inflammatory changes in the perilesional regions of these tumors
seem also to participate in the generation of seizures. Some other
possible mechanisms of epileptogenesis in high-grade gliomas are
the perilesional focal ischemia, deafferentation of cortical areas by
mass effect, and also increased iron in minor bleeding (Beaumont
and Whittle, 2000).
The seizures disrupt the BBB, enhance inflammatory
responses, increase glutamate excitotoxicity and cell apoptosis,
and substantially increase cognitive and psychological morbidity.
Several studies have described variations in neurovascular
integrity and disturbances of the BBB with neuronal
hypersynchronization and epileptiform activity (Liebner et al.,
2000). Molecular changes in brain tumors can affect the BBB
structure and functions, including decreased expression of
transmembrane junctional proteins. Disruption of the BBB may
also lead to abnormal extravasation of plasma protein and other
substances, including glutamate, contributing to hyperexcitability
and development of seizure focus (Ivens et al., 2007).
The BBB has an important role in the immune response,
with elevated production of inflammatory cytokines (Vezzani
and Granata, 2005). The supraregulation of adhesion molecules
and metalloproteinases contributes to the changes in the BBB
permeability.
Because seizures substantially increase morbidity and some
patients evolve with medically refractory epilepsy, it is important
to understand the mechanism of action and the effect of the drug
of choice for treating these patients. The recurrence or worsening
of seizures is often associated with tumor recidivism in GBM,
and they require additional pharmacological treatment, which
can be hard to manage because of the many drug interactions and
cumulative side effects.
The current consensus is that all patients with brain tumors
presenting with or having seizures should be treated with
antiepileptic drugs (AEDs), because of the high risk of recur-
rence of seizures. The first-line AEDs, including valproate (VPA),
phenytoin and carbamazepine, have demonstrated many major
side effects and dangerous interactions with chemotherapeutic
and antitumor drugs. The most commonly seen side effects
with these drugs are cognitive impairment, liver dysfunction,
dermatological reactions and bone-marrow suppression. Sev-
eral studies have found that side effects are more common
in patients with brain tumors than in the general epileptic
population.
Drug interactions between AEDs and commonly used tumor
therapies can lead to inadequate control of the seizures or sub-
therapeutic treatment of the tumor. Toxic effects have also been
noted. Many of the common AEDs, especially carbamazepine,
phenytoin and phenobarbital, induce cytochrome P450 enzymes,
which accelerate the metabolism, reducing the half-life of corti-
costeroids and many other chemotherapy drugs that in this con-
text exhibit decreased therapeutic effectiveness. Some chemother-
apeutic agents also induce the P450 system, lowering concentra-
tions of the AED.
Among the older AEDs, valproate, in doses of 1–3 g per
day, has been claimed to be the drug of choice because of its
anticonvulsive efficacy. It has an intravenous formulation, which
is very useful in perioperative management and also in cases of
status epilepticus, which is seen in up to 26% of these patients,
with the overall mortality rate reaching 30–40%. Also, its action as
a histone deacetylase inhibitor may reduce proliferation rates and
promote differentiation of cancer stem cells, the main mechanism
responsible for tumor recidivism in the case of GBM (Alvarez
et al., 2014). Valproate may increase the hematological toxicity
of the chemotherapy and may independently impair hemostasis,
which is of some concern for these patients, who will often require
surgical procedures.
Within the past 10 years, several new AEDs including lamotrig-
ine, oxcarbazepine, topiramate, levetiracetam (LEV), lacosamide
and zonizamide have emerged that are without clinically impor-
tant drug interactions. Most of them have shown similarly good
efficacy, with better tolerability for oxcarbazepine, lacosamide and
lamotrigine. Most data were based on uncontrolled retrospective
studies. Of this group, only levetiracetam and lacosamide have
intravenous formulations.
Many studies have now proposed levetiracetam as the drug
of choice in the treatment and prevention of peri- and post-
operative seizures, in daily doses of 1.5–3 or 4 g. Levetirac-
etam has the advantages of excellent bioavailability (100%,
equivalent to the venous formulation), no protein binding,
no liver-metabolism or enzyme-inducer effect, and a very
good tolerability profile. It has a completely different mecha-
nism of action, binding to the Synaptic Vesicle Protein 2 A,
thus inhibiting neurotransmitter release. It also has shown
histone deacetylase inhibitor, anti-inflammatory and antioxi-
dant effects. Many recent trials have demonstrated its anti-
convulsive efficacy and safety in the control of perioperative
(88 to 100% seizure control) and long-term epileptic seizures
(91% seizure freedom), as well as in the treatment of status
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epilepticus when combined with phenytoin (Claassen et al.,
2003) or with phenytoin and pregabalin (trifecta trial with
70% success in halting the status epilepticus; Swisher et al.,
2012).
In a retrospective comparative study between valproate and
levetiracetam with 282 patients with supratentorial brain tumors
(Lee et al., 2013), the two drugs showed comparable efficacy
(ca. 7% of patients experienced postoperative seizures) and much
better tolerability for levetiracetam (long-term complication rates
of 26.8% for VPA and 9.8% for LEV). Moreover, 38.5% in the VPA
group changed to or added another AED, whereas only 17.6% in
the LEV group did so. Another retrospective comparative study
(Kerkhof et al., 2013) with 291 GBM patients treated with VPA
alone, with LEV alone or with a combination of the two as a
second option in the refractory group, also showed a similar
efficacy in seizure control (seizure freedom of 78% for VPA
and 70% for LEV), although VPA was slightly superior with
respect to the overall long-term survival rate, with a 2-month-
longer survival. The polytherapy with VPA and LEV combined
added 60% seizure freedom in both refractory monotherapy
groups.
The clinical management of seizures in this context is complex,
requiring experts in this field, measurement of serum levels of the
antiepileptic and oncologic drugs, serial blood analysis, monitor-
ing of clinical side effects, and keeping in mind that the recurrence
of seizures may represent a tumor recurrence.
CONCLUSION AND PERSPECTIVES
In this review, we have pointed out and discussed the implications
of the interactions between normal glia or glioma cells and the
BBB. Since its first discovery by Edwin E. Goldman, considerable
progress has been made in the understanding of BBB. Although
100 years have passed since the BBB discovery, the mechanisms by
which some drugs or parasites enter the brain are still unsolved.
Furthermore, the real interactions of the endothelial cells with
the extra-endothelial components of the brain microenvironment
remain unclear. It is not completely understood how astrocytes
endfeet interact with BBB and the astrocytoma derived signals
that lead to an intense vasculogenesis into the tumor. Interest-
ingly, GBM and BBB interactions may occur via extracellular
proteins. For instance, the imbalance of tenascin and fibronectin
in the tumor contributes to vessel formation as we have previously
demonstrated (Alves et al., 2011a). Glioblastoma, a dramatic
and fatal tumor that grows into the brain, can create a scenario
of seizures very difficult to control. The growth of this tumor
can also promote disruption of vessels, generating edema, which
complicates the health status of the patient. It is clear that novel
methods to control GBM growth and BBB disruption are neces-
sary to solve these severe complications.
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